New guideline concerning CYP2D6 and atomoxetine
In March 2019, the Clinical Pharmacogenetics Implementation Consortium (CPIC) published a new guideline concerning CYP2D6 and atomoxetine, a non-stimulant medication used in the treatment of some people with attention-deficit/hyperactivity disorder. Currently, this drug is included in the TreatGx pharmacogenetic report and precision prescribing software, and we provide relevant information to ...